(NASDAQ: NASDAQ:VKTX), whose stock has delivered an impressive 114% return over the past year, has launched a Phase 2 clinical trial for... Viking Therapeutics, Inc. (NASDAQ:VKTX) today announced the ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...